Literature DB >> 18685007

Comparison of GP5+/6+-PCR and SPF10-line blot assays for detection of high-risk human papillomavirus in samples from women with normal cytology results who develop grade 3 cervical intraepithelial neoplasia.

A T Hesselink1, M A P C van Ham, D A M Heideman, Z M A Groothuismink, L Rozendaal, J Berkhof, F J van Kemenade, L A F G Massuger, W J G Melchers, C J L M Meijer, P J F Snijders.   

Abstract

Using a case control approach, we performed a two-way comparison study between GP5+/6+-PCR and HPV SPF(10)-Line Blot 25 (SPF(10)) assays for detection of 14 types of high-risk human papillomavirus (hrHPV) in samples from women with normal cytology results who had or developed grade 3 cervical intraepithelial neoplasia (CIN 3). Samples were pooled from two cohorts, i.e., women participating in population-based screening and women attending a gynecological outpatient clinic. Cases (n = 45) were women with histologically confirmed CIN 3 diagnosed within a median follow-up time of 2.7 (range, 0.2 to 7.9) years. Control samples were from women (n = 264) who had developed CIN 1 lesions at maximum (median follow-up at 5.8 [range, 0 to 10] years). Identical numbers of cases tested positive for 1 or more of the 14 hrHPV types by both systems (40/45; McNemar; P = 1.0). Conversely, SPF(10) scored significantly more controls as hrHPV positive than did GP5+/6+-PCR (95/264 versus 29/264; McNemar; P < 0.001). Consequently, women with normal cytology results and an hrHPV GP5+/6+-PCR-positive test exhibited a risk of CIN 3 that was 4.5 times higher (odds ratio [OR], 65; 95% confidence interval [95%CI], 24 to 178) than that seen for women with an hrHPV-positive SPF(10) test (OR, 14; 95%CI, 5 to 38)). Similar results were obtained after analysis of both cohorts separately. Discrepancy analysis by viral load assessment for the most common discordant hrHPV types (HPV16, -18, and -52) showed that samples which were SPF(10) positive only for these types had viral loads significantly lower than those for samples that were positive by both assays (analysis of variance; P < or = 0.006). Our data indicate that GP5+/6+-PCR has a better clinical performance than SPF(10) for women who are diagnosed with CIN 3 after prior normal cytology results. The extra positivity scored by SPF(10) mainly involved infections characterized by low viral loads that do not result in CIN 3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18685007      PMCID: PMC2566115          DOI: 10.1128/JCM.00476-08

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  34 in total

1.  Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology.

Authors:  Peter J F Snijders; Cornelis J A Hogewoning; Albertus T Hesselink; Johannes Berkhof; Feja J Voorhorst; Maaike C G Bleeker; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2006-09-01       Impact factor: 7.396

2.  The expanded use of HPV testing in gynecologic practice per ASCCP-guided management requires the use of well-validated assays.

Authors:  Mark H Stoler; Philip E Castle; Diane Solomon; Mark Schiffman
Journal:  Am J Clin Pathol       Date:  2007-03       Impact factor: 2.493

3.  Cross-sectional comparison of an automated hybrid capture 2 assay and the consensus GP5+/6+ PCR method in a population-based cervical screening program.

Authors:  A T Hesselink; N W J Bulkmans; J Berkhof; A T Lorincz; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2006-10       Impact factor: 5.948

4.  Human papillomavirus type-specific 18-month risk of high-grade cervical intraepithelial neoplasia in women with a normal or borderline/mildly dyskaryotic smear.

Authors:  Johannes Berkhof; Nicole W J Bulkmans; Maaike C G Bleeker; Saskia Bulk; Peter J F Snijders; Feja J Voorhorst; Chris J L M Meijer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-07       Impact factor: 4.254

Review 5.  HPV testing in cervical screening.

Authors:  Antoinette A T P Brink; Peter J F Snijders; Chris J L M Meijer; Johannes Berkhof; René H M Verheijen
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2005-12-13       Impact factor: 5.237

6.  Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months.

Authors:  Saskia Bulk; Nicole W J Bulkmans; Johannes Berkhof; Lawrence Rozendaal; A Joan P Boeke; René H M Verheijen; Peter J F Snijders; Chris J L M Meijer
Journal:  Int J Cancer       Date:  2007-07-15       Impact factor: 7.396

7.  Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial.

Authors:  N W J Bulkmans; J Berkhof; L Rozendaal; F J van Kemenade; A J P Boeke; S Bulk; F J Voorhorst; R H M Verheijen; K van Groningen; M E Boon; W Ruitinga; M van Ballegooijen; P J F Snijders; C J L M Meijer
Journal:  Lancet       Date:  2007-10-04       Impact factor: 79.321

8.  Human papillomavirus and Papanicolaou tests to screen for cervical cancer.

Authors:  Pontus Naucler; Walter Ryd; Sven Törnberg; Anders Strand; Göran Wadell; Kristina Elfgren; Thomas Rådberg; Björn Strander; Bo Johansson; Ola Forslund; Bengt-Göran Hansson; Eva Rylander; Joakim Dillner
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

9.  Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

Authors:  Marie-Hélène Mayrand; Eliane Duarte-Franco; Isabel Rodrigues; Stephen D Walter; James Hanley; Alex Ferenczy; Sam Ratnam; François Coutlée; Eduardo L Franco
Journal:  N Engl J Med       Date:  2007-10-18       Impact factor: 91.245

10.  Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica.

Authors:  Mahboobeh Safaeian; Rolando Herrero; Allan Hildesheim; Wim Quint; Enrique Freer; Leen-Jan Van Doorn; Carolina Porras; Sandra Silva; Paula González; M Concepcion Bratti; Ana Cecilia Rodriguez; Philip Castle
Journal:  J Clin Microbiol       Date:  2007-03-07       Impact factor: 5.948

View more
  14 in total

1.  Comparison of the clinical performance of PapilloCheck human papillomavirus detection with that of the GP5+/6+-PCR-enzyme immunoassay in population-based cervical screening.

Authors:  A T Hesselink; D A M Heideman; J Berkhof; F Topal; R P Pol; C J L M Meijer; P J F Snijders
Journal:  J Clin Microbiol       Date:  2009-12-30       Impact factor: 5.948

2.  The indicating FTA elute cartridge a solid sample carrier to detect high-risk HPV and high-grade cervical lesions.

Authors:  Roosmarie P de Bie; Channa E Schmeink; Judith M J E Bakkers; Peter J F Snijders; Wim G V Quint; Leon F A G Massuger; Ruud L M Bekkers; Willem J G Melchers
Journal:  J Mol Diagn       Date:  2011-04-29       Impact factor: 5.568

3.  Dry storage and transport of a cervicovaginal self-sample by use of the Evalyn Brush, providing reliable human papillomavirus detection combined with comfort for women.

Authors:  Romy van Baars; Remko P Bosgraaf; Bram W A ter Harmsel; Willem J G Melchers; Wim G V Quint; Ruud L M Bekkers
Journal:  J Clin Microbiol       Date:  2012-09-26       Impact factor: 5.948

4.  Development and characterization of the cobas human papillomavirus test.

Authors:  Arundhati Rao; Stephen Young; Henry Erlich; Sean Boyle; Mark Krevolin; Rita Sun; Raymond Apple; Catherine Behrens
Journal:  J Clin Microbiol       Date:  2013-02-27       Impact factor: 5.948

5.  Near-infrared Raman Microspectroscopy Detects High-risk Human Papillomaviruses.

Authors:  Elizabeth Vargis; Yi-Wei Tang; Dineo Khabele; Anita Mahadevan-Jansen
Journal:  Transl Oncol       Date:  2012-06-01       Impact factor: 4.243

6.  A human papilloma virus testing algorithm comprising a combination of the L1 broad-spectrum SPF10 PCR assay and a novel E6 high-risk multiplex type-specific genotyping PCR assay.

Authors:  Dirk van Alewijk; Bernhard Kleter; Maarten Vent; Jean-Marc Delroisse; Maurits de Koning; Leen-Jan van Doorn; Wim Quint; Brigitte Colau
Journal:  J Clin Microbiol       Date:  2013-01-30       Impact factor: 5.948

7.  Comparison of Two Widely Used Human Papillomavirus Detection and Genotyping Methods, GP5+/6+-Based PCR Followed by Reverse Line Blot Hybridization and Multiplex Type-Specific E7-Based PCR.

Authors:  Gary M Clifford; Salvatore Vaccarella; Silvia Franceschi; Vanessa Tenet; M Chantal Umulisa; Ugyen Tshomo; Bolormaa Dondog; Alex Vorsters; Massimo Tommasino; Daniëlle A M Heideman; Peter J F Snijders; Tarik Gheit
Journal:  J Clin Microbiol       Date:  2016-05-25       Impact factor: 5.948

8.  Establishment and characterization of a penile cancer cell line, penl1, with a deleterious TP53 mutation as a paradigm of HPV-negative penile carcinogenesis.

Authors:  Jieping Chen; Kai Yao; Zaishang Li; Chuangzhong Deng; Liangjiao Wang; Xingsu Yu; Peili Liang; Qiankun Xie; Peng Chen; Zike Qin; Yunlin Ye; Zhuowei Liu; Fangjian Zhou; Zhenfeng Zhang; Hui Han
Journal:  Oncotarget       Date:  2016-08-09

Review 9.  A review of methods for detect human Papillomavirus infection.

Authors:  André L P Abreu; Raquel P Souza; Fabrícia Gimenes; Marcia E L Consolaro
Journal:  Virol J       Date:  2012-11-06       Impact factor: 4.099

10.  Distribution of Human Papillomavirus Genotypes in Iranian Women According to the Severity of the Cervical Lesion.

Authors:  Mostafa Salehi-Vaziri; Farzin Sadeghi; Firoozeh Sadat Hashemi; Hayedeh Haeri; Farah Bokharaei-Salim; Seyed Hamidreza Monavari; Hossein Keyvani
Journal:  Iran Red Crescent Med J       Date:  2016-01-31       Impact factor: 0.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.